MedTrace Logo

The Mass Balance Study of LP-168 in Healthy Subjects

NCT06126861 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-03-15

No results posted yet for this study

Summary

This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption characteristics, as well as to evaluate the metabolism and elimination pathways after a single oral dose of 150mg, 100μCi \[14C\]LP-168 in healthy subjects.

Conditions

  • Clinical Pharmacology

Interventions

DRUG

[14C]LP-168

single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state

Sponsors & Collaborators

  • Guangzhou Lupeng Pharmaceutical Company LTD.

    lead INDUSTRY

Principal Investigators

  • Liyan Miao, MD · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-25
Primary Completion
2024-02-02
Completion
2024-03-13
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06126861 on ClinicalTrials.gov